Cerebrovascular disease is one of the three principal diseases that can cause people to die. Acute cerebral infarction which occupies 70% of cerebrovascular disease has a disability rate of 50%-70% and a recurrence rate of 40%. And one thing to be noted is that the more relapses people have, the higher the mortality and disability.
Acute cerebral infarction, one of the serious threats to old people's health, features sudden onset, complex pathogenesis and three high and one low: high morbidity, high mortality, high fatality and low cure rate. Edaravone injection, a life-saving drug for the treatment of acute cerebral infarction, is the only free radical scavenger in the world with a clear mechanism and target of acute cerebral infarction. Ever since its debut in Japan in 2002, its sales in the first 13 months has surpassed JPY 40 billion.
Simcere is China's first and world's second manufacturer of edaravone injection. Its new product Bi Cun is priced at 1/33 of the price of similar products in Japan. In 2007, Bi Cun spread over China with a market share of 74.62%. According to statistics, edaravone developed fast after entering China, annual sales value rose from less than CNY 50 million in 2005 to CNY 629 million in 2014 and CAGR reaching up to 34.3% during the period of 2005-2015. Currently, local manufacturers of edaravone are as follows: Simcere, Jilin Boda Pharmaceutical Co., Ltd, Jilin Province Huinan Changlong Biopharmacy Co., Ltd and Kunming Jida Pharmaceutical Co., Ltd, among which Simcere has the largest market share of 39% with sales value reaching up to CNY 246 million in 2014.
Key Topics Covered:
1 Related Concepts of Edaravone
2 Market Profile of Edaravone in China
3 Survey on Sales Status of Edaravone in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Edaravone in China, 2010-2014
5 Survey on Dosage Forms of Edaravone in China, 2010-2014
6 Reference Price of Edaravone in Chinese Hospitals in 2014
7 Major Manufacturers of Edaravone in Chinese Market, 2010-2014